Exelixis Access Services: EASE

Patient Support Services Guide 2018


Cabometyx
844-900-3273
Cometriq
855-253-3273

Exelixis Access Services (EASE) includes a set of personalized support programs that offer a full range of services designed to support healthcare providers and patients who are prescribed Cabometyx (cabozantinib) or Cometriq (cabozantinib).

Cabometyx is a kinase inhibitor indicated for the treatment of patients with advanced renal-cell carcinoma who have received anti-angiogenic therapy. Cometriq is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (Table).

EASE Programs

The EASE program services provide financial, access, and reimbursement support.

Co-pay Assistance Program

Eligible commercially insured patients pay no more than $10 a month.

Patient Assistance Program

For patients who are underinsured or uninsured, this program provides Exelixis medications free of charge.

Quick Start Program

Patients who experience delays with insurance coverage determination do not have to wait to initiate treatment. New patients who experience a payer delay of more than 5 days can receive a 15-day supply of Cabometyx, with refills up to 60 days.

Dose Exchange Program

Patients who require a dose reduction to their therapy with Cabometyx can receive a free, 1-time supply of Cabometyx tablets in the new dose strength.

Eligibility

Co-pay Assistance Program

To be eligible for this program, patients must have commercial health insurance and be prescribed Cabometyx or Cometriq for an approved indication.

Patient Assistance Program

The Patient Assistance Program offers Cabometyx or Cometriq for patients who are uninsured or underinsured, and meet the Patient Assistance Program eligibility criteria.

Quick Start Program

New patients with a diagnosis for which Cabometyx is indicated who experience a payer delay of more than 5 days can receive a 15-day supply of Cabometyx, with refills up to 60 days.

Dose Exchange Program

The Dose Exchange Program is only available for Cabometyx dose reductions. Patients may receive a 1-time, 15-day supply of 40 mg and 20 mg of the drug through the Dose Exchange Program. Patients are required to return unused drugs.

Application & Enrollment

The enrollment process for the EASE program is drug-specific. The application for the Cabometyx EASE program requires completion of the EASE Enrollment and Patient Authorization forms. These must be submitted by fax to 844-901-3273, along with a copy of the insurance card. More information about the EASE program for Cabometyx can be obtained by calling 844-900-3273.

Information about enrollment in the Cometriq EASE program can be obtained by calling 855-253-3273.

Other Services

The EASE program provides additional services for Cabometyx and for Cometriq.

Access and Reimbursement Support provides assistance for dedicated support specialists who help healthcare professionals with regard to benefit investigations, prior authorizations, appeals, and delivery coordination.

Table Exelixis Oncology Drugs

Drugs
Indications
Patient support programs

Drug
Cabometyx (cabozantinib)
Indication
Advanced renal-cell carcinoma

Drug
Cometriq (cabozantinib)
Indication
Progressive, metastatic medullary thyroid cancer